Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2008 Sep;23(9):1441-6.
doi: 10.1007/s11606-008-0690-1. Epub 2008 Jun 20.

EDUC'AVK: reduction of oral anticoagulant-related adverse events after patient education: a prospective multicenter open randomized study

Gilles Pernod  1 , José Labarère, Jacqueline Yver, Bernadette Satger, Benoit Allenet, Touffek Berremili, Michèle Fontaine, Guy Franco, Jean Luc Bosson
Affiliations
Randomized Controlled Trial

EDUC'AVK: reduction of oral anticoagulant-related adverse events after patient education: a prospective multicenter open randomized study

Gilles Pernod et al. J Gen Intern Med. 2008 Sep.

Abstract

Background: Long-term oral anticoagulation treatment is associated with potential morbidity. Insufficient patient education is linked to poorly controlled anticoagulation. However the impact of a specific educational program on anticoagulation related morbidity remains unknown.

Objective: To evaluate the effect of an oral anticoagulation patient education program in reducing both hemorrhagic and recurrent thrombotic complications.

Design/participants: We conducted a prospective, multicenter open randomized study, comparing an interventional group who received a specific oral anticoagulation treatment educational program with a control group. Eligible patients were older than 18 and diagnosed as having deep vein thrombosis or pulmonary embolism requiring therapy with a vitamin K antagonist for 3 months or more. Our primary outcome was the occurrence of hemorrhagic or thromboembolic events.

Results: During the 3-month follow-up the main outcome criteria were observed 20 times (6.6% of patients), 5 (3.1%) in the experimental and 15 (10.6%) in the control group. Consequently, in multivariate analysis, the cumulative risk reduction in the experimental group was statistically significant (OR 0.25, 95% CI 0.1-0.7, p < 0.01).

Conclusions: Patient education using an educational program reduced VKA-related adverse event rates.

PubMed Disclaimer

References

    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1056/NEJM199705223362107', 'is_inner': False, 'url': 'https://doi.org/10.1056/nejm199705223362107'}, {'type': 'PubMed', 'value': '9154771', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/9154771/'}]}
    2. Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med. 1997;336:1506–11. - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1111/j.1365-2141.2005.05417.x', 'is_inner': False, 'url': 'https://doi.org/10.1111/j.1365-2141.2005.05417.x'}, {'type': 'PubMed', 'value': '15801958', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/15801958/'}]}
    2. Palareti G, Legnani C, Guazzaloca G, et al. Risks factors for highly unstable response to oral anticoagulation: a case-control study. Br J Haematol. 2005;129:72–8. - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1378/chest.126.3_suppl.401S', 'is_inner': False, 'url': 'https://doi.org/10.1378/chest.126.3_suppl.401s'}, {'type': 'PubMed', 'value': '15383479', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/15383479/'}]}
    2. Büller HR, Agnelli G, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease. The seventh ACCP consensus conference on antithrombotic and thrombolytic therapy. Chest. 2004;126:420S–28S. - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1056/NEJMoa035029', 'is_inner': False, 'url': 'https://doi.org/10.1056/nejmoa035029'}, {'type': 'PubMed', 'value': '12601075', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/12601075/'}]}
    2. Ridker PM, Goldhaber SZ, Danielson E, et al. PREVENT Investigators. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med. 2003;348:1425–34. - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1056/NEJMoa035422', 'is_inner': False, 'url': 'https://doi.org/10.1056/nejmoa035422'}, {'type': 'PubMed', 'value': '12917299', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/12917299/'}]}
    2. Kearon C, Ginsberg JS, Kovacs MJ, et al. Extended Low-Intensity Anticoagulation for Thrombo-Embolism Investigators. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med. 2003;349:631–9. - PubMed

Publication types